NCT07222566
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 484 → 560 locations
- Minor Trial sites expanded: 479 → 484 locations
- Notable Eligibility criteria expanded, about 39 words
- Trial sites expanded: 440 → 479 locations
- Secondary endpoints: details revised at 2 of 13 entries
- Minor Trial sites expanded: 413 → 440 locationsv9
- Minor Trial sites expanded: 373 → 413 locationsv8
- Minor Trial sites expanded: 346 → 373 locationsv7
- Minor Trial sites expanded: 251 → 346 locationsv6
- Minor Trial sites expanded: 229 → 251 locationsv5
- Minor Trial sites expanded: 153 → 229 locationsv4
- Minor Trial sites expanded: 17 → 153 locations
- Secondary endpoints revised (13)
- Study title expanded, about 2 words
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Enrollment target: 1500 to 1410
- Study sites: 0 to 17
- Start date changed from estimate of Dec 5, 2025 to Jan 6, 2026
- Secondary endpoints revised (13)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Participants will receive PF-08634404 combined with chemotherapy regimen 1, followed by maintenance therapy with PF-08634404.
Participants will receive pembrolizumab combined with chemotherapy regimen 1, followed by maintenance therapy with pembrolizumab.
Participants will receive PF-08634404 combined with chemotherapy regimen 2, followed by maintenance therapy with PF-08634404 and chemotherapy.
Participants will receive pembrolizumab combined with chemotherapy regimen 2, followed by maintenance therapy with pembrolizumab and chemotherapy.
Biologicals: PF-08634404, Pembrolizumab
Drugs: Chemotherapy Regimen 1, Chemotherapy Regimen 2
Sites
560 sites in 21 countries
United States 278, China 44, Japan 31, Spain 22, Brazil 20, Germany 15, India 15, Turkey (Türkiye) 15, Italy 14, Argentina 13, Australia 11, Taiwan 11, Canada 10, Greece 9, Poland 9, South Korea 9, France 8, Hungary 8, Czechia 7, Israel 6, Puerto Rico 5